Published Articles
2021
SEPTEMBER, 10, 2021 – Overcoming Development Obstacles to the Deliver of Effective Ocular Therapy
MARCH, 26 2021 – Advancements in drug delivery for women’s health and beyond
MARCH 1, 2021 – Improving Bioavailability & Solubility: Each Molecule Is Unique
FEBRUARY 23, 2021 – Solubility and Bioavailability Enhancement Techniques
JANUARY 27, 2021 – Parenteral Drug Delivery Trends
JANUARY, 20, 2021 – A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
JANUARY 18.2021 – Top pharma industry predictions for 2021
2020
NOVEMBER, 20 2020 – New Horizons for Patient-Centric Drug Delivery
NOVEMBER 1, 2020 – Long-Acting Drug Delivery: Injections, Implants, and Combination Products
OCTOBER, 5 2020 – Why drug developers should take a fresh look at long-acting dosage forms
AUGUST 1, 2020 – Drug Dosage Forms – Innovations That Shouldn’t Be Given A MISS
AUGUST 1, 2020 – How Aseptic Nanomilling Can Provide a Solution for Today’s Insoluble Compounds Including HPCs
JULY 1, 2020 – Demand for Custom Dosage Forms Fuels Innovation
JUNE 1, 2020 – Good Manufacturing Practices: Challenges with Compliance
JUNE 1, 2020 – Outsourcing Formulation Development & Manufacturing: Specialized Capabilities for Small & Large Molecules
MARCH 10, 2020 – Improving Bioavailability & Solubility
MARCH 6, 2020 – Women in Pharma: Reimagining the Glass Ceiling
MARCH 6, 2020 – The Year That Was and the Year That Will Be
MARCH 1, 2020 – Seeking Early Answers to Formulation Questions
JANUARY 24, 2020 – Optimizing Ophthalmic Drug Delivery for Therapeutic Effectiveness
2019
DECEMBER 2, 2019 – Nanomilling: Shaping the Solubility and Bioavailability of Today’s Therapeutics
NOVEMBER 6, 2019 – Overcoming the Challenges in Drug-Device Combination Product Formulation
NOVEMBER 6, 2019 – The Demands of the Perfect Dose
SEPTEMBER 29, 2019 – Women’s Equality Day: Pharma is Leveling the Playing Field
SEPTEMBER 1, 2019 – Combination Products for Medical Device Developers
AUGUST 29, 2019 – Overcoming Complexity – Trends Shaping The Drug Formulation Industry
JUNE 18, 2019 – Looking Beyond the Solubility Horizon
JUNE 15, 2019 – The Big Freeze: Obtaining the Best Results from Lyophilization
JUNE 13, 2019 – Outsourcing Formulation Development & Manufacturing: CDMOs Shift to Offer More Specialized Services
APRIL 29, 2019 – Drug-Eluting Devices: Delivering on Drug Delivery’s Combined Potential
APRIL 29, 2019 – Patient-Centric Drug Development Comes of Age
APRIL 20, 2019 – Ask the Expert: Analytical Method Validation
MARCH 16, 2019 – Particle Sciences’ Barbara Morgan on Pharma and Diversity
MARCH 11, 2019 – Improving Bioavailability & Solubility: Chemical & Physical Modification vs. Formulation Development
2018
DECEMBER 11, 2018 – Dissolving Solubility Challenges
NOVEMBER 19, 2018 – Early-Stage Formulation Considerations
SEPTEMBER 29, 2018 – American Pharma Review – An Overview of the Zeta Potential – Part 1: The Concept
2016
APRIL 10, 2016 – Particle Sciences — Targeted Drug Products Using Nano Formulations
MARCH 29, 2016 – Particle Sciences — An API’s Characteristics Determine the Best Approach to Improving Solubility
2015
JANUARY 29, 2015 – Particle Sciences Positions Itself as a Bioavailability Tool for Most Drug Forms
2014
SEPTEMBER 9, 2014 – Vaccine Technologies & the Rationale for New Nanoparticle Formulations
2013
NOVEMBER 19, 2013 – Particle Sciences is Highlighted in the CHAARM Newsletter 2013
SEPTEMBER 29, 2013 – The Central Role Of Analytic Method Development And Validation In Pharmaceutical Development
2012
DECEMBER 12, 2012 – Observations on Nanotechnology-based Drug Delivery Approaches: Translating Nanotechnology from Bench to Pharmaceutical Market
AUGUST 29, 2012 – Comments On Biopharmaceutical Classification System And Formulation Development
MARCH 11, 2012 – Solid Dosage Forms – Polymers for Solid Oral Dosage Forms
JANUARY 29, 2012 – Bioavailability Enhancement: A Novel Spray-Drying Technology to Improve the Bioavailability of Biopharmaceutical Classification System Class II Molecules
2011
SEPTEMBER 20, 2011 – The Zeta Potential & its Use in Pharmaceutical Applications – Part 2: Measurement Techniques & Uses
AUGUST 11, 2011 – Charged Interfaces in Polar & Non-Polar Media & the Concept of the Zeta Potential
MAY 22, 2011 – Particle Sciences & Horiba Instruments: Providing Clients a Total Solution
2010
NOVEMBER 29, 2010 – Microbicides: A promising strategy to reduce HIV infection
OCTOBER 29, 2010 – The relentless effort to curtail the HIV pandemic continues as researchers aggressively investigate alternative prevention tools
SEPTEMBER 7, 2010 – Update from CHAARM, a Particle Sciences Client
AUGUST 29, 2010 – Particle Sciences: Providing Formulation & Analytic Services to Meet Demanding Drug Delivery Challenges
JULY 2, 2010 – Selection of Active Pharmaceutical Ingredients (APIs) and Excipients for Topical Formulations
JUNE 14, 2010 – Forced Degradation as an Integral Part of HPLC Stability-Indicating Method Development
2009
SEPTEMBER 23, 2009 – Solid Lipid Nanoparticles: Drug Delivery Technology September 2009 Vol 9 No 8. Solid Lipid Nanoparticles for the Delivery of Pharmaceutical Actives.
MARCH 29, 2009 – The Issues & Challenges Involved in In Vitro Release Testing for Semi-Solid Formulations
2007
DECEMBER 29, 2007 – Particle Size Distribution: Light Microscopic Determination of Particle Size Distribution in an Aqueous Gel.
OCTOBER 31, 2007 – Identification Of Human Natriuretic Hormone Cain Et Al PNAS October 31, 2007
APRIL 28, 2007 – Microcapsules With Liquid Cores And Polymer Shells Made By Solvent Evaporation
FEBRUARY 28, 2007 – Microencapsulated Non-aqueous Dispersions
2006
OCTOBER 28, 2006 – pH-sensitive Microgels
OCTOBER 28, 2006 – Manufacture Of Microspheres As Carrier Particles For Active Biomolecules
JUNE 8, 2006 – Targeted Delivery Of Actives: Cationic Nanoparticles For Use In Hair And Skin Products
APRIL 29, 2006 – Dry Eye Syndrome: A Review & Novel Formulation Approach
APRIL 28, 2006 – Nebulizable Nanoparticle Dispersions: A Novel Inhalable Dosage Form
APRIL 8, 2006 – A Review Of Sunscreen Safety And Efficacy
2005
MAY 7, 2005 – Microbicides For HIV AIDS Electrophoretic Fingerprinting The H9 Cell Model System
JANUARY 17, 2005 – Phase III Modeling AIDS 06
2004
DECEMBER 28, 2004
TMC120 Blocks HIV-1 Infection In Cellular And Human Cervical Tissue Models
JUNE 28, 2004 – Regulatory Challenges In Microbicide Development